Scarica l'app Stockscreener
1.82
2.25%
0.04
Dopo l'orario di chiusura:
1.82
Precedente Chiudi:
$1.78
Aprire:
$1.8
Volume 24 ore:
17,034
Relative Volume:
0.14
Capitalizzazione di mercato:
$4.18M
Reddito:
-
Utile/perdita netta:
$-9.32M
Rapporto P/E:
-0.1432
EPS:
-12.7107
Flusso di cassa netto:
$-7.30M
1 W Prestazione:
+9.64%
1M Prestazione:
+22.97%
6M Prestazione:
-11.22%
1 anno Prestazione:
-45.02%
Intervallo 1D:
$1.7484
$1.85
Intervallo di 1 settimana:
$1.6109
$1.96
Portata 52W:
$0.952
$6.39
Tharimmune Inc Stock (THAR) Company Profile
Nome
Tharimmune Inc
Settore
Industria
Telefono
302-743-2995
Indirizzo
1200 ROUTE 22 EAST, BRIDGEWATER
Confronta THAR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
THAR
Tharimmune Inc
|
1.82 | 4.18M | 0 | -9.32M | -7.30M | -12.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Tharimmune Inc Borsa (THAR) Ultime notizie
Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors - The Holland Sentinel
EON Resources Inc. Announcement - Worcester Telegram
AINOS (NASDAQ: AIMD) Signs Long-Form Interview and National TV Commercial Agreement with New to The Street - Lubbock Avalanche-Journal
Tharimmune announces key leadership changes to advance pipeline - Investing.com
Navy SEAL Commander Joins Biotech Developing Military Defense Against Weaponized Fentanyl - Stock Titan
Don Kim Resigns as CFO of Tharimmune effective immediatelySEC filing - MarketScreener
Interactive Strength Inc. (Nasdaq:TRNR) Closes Initial $55 Million Investment for Crypto Treasury Strategy and Begins Acquiring $FET - Lohud
Hawley Crescent Catering & Events Wins 2025 Consumer Choice Award for Catering Excellence in Durham Region - Cincinnati Enquirer
Tharimmune announces executive changes and new agreements - Investing.com Australia
Tharimmune announces executive changes and new agreements By Investing.com - Investing.com Nigeria
TharimmuneRandy Milby Resigns As CEO And Board Member - marketscreener.com
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025 - IndyStar
Tharimmune Holds Annual Meeting, Elects Directors - TipRanks
Tharimmune (THAR) Appoints Strategic Advisor to Enhance TH104 De - GuruFocus
Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback - Jonesboro Sun
FDA Clears Path for Tharimmune's Military Fentanyl Defense Drug as Navy SEAL Commander Joins Advisory Team - Stock Titan
Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Tharimmune, Inc. SEC 10-Q Report - TradingView
Tharimmune appoints new executive chairman By Investing.com - Investing.com India
Tharimmune appoints new executive chairman - Investing.com Australia
Tharimmune IncAppoints Vincent Lopriore As Executive ChairmanSEC Filing - marketscreener.com
Tharimmune (THAR) Reports Promising Phase 1 Results for TH104 Bu - GuruFocus
Tharimmune (THAR) Advances TH104 as Key Medical Countermeasure | - GuruFocus
Tharimmune advances opioid prophylaxis drug TH104 - Investing.com
Tharimmune advances opioid prophylaxis drug TH104 By Investing.com - Investing.com South Africa
Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback - Weatherford Democrat
Tharimmune's New Drug Breakthrough: FDA Fast-Tracks Military Protection Against Weaponized Fentanyl - Stock Titan
Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences - Chronicle-Tribune
Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors - Bluefield Daily Telegraph
Stocks of Tharimmune Inc (THAR) are poised to climb above their peers - Sete News
Breakthrough Drug TH104 Clinical Data Selected for Two Premier Medical Conferences DDW and EASL - Stock Titan
Tharimmune Appoints Clay Kahler And Gary Stetz To Board - citybiz
Tharimmune (THAR) Expands Board with New Appointments | THAR Sto - GuruFocus
Tharimmune expands board with two new directors By Investing.com - Investing.com India
Tharimmune expands board with two new directors - Investing.com
Tharimmune Adds $500M Success Story Entrepreneur and Financial Expert to Board Leadership - Stock Titan
Tharimmune Inc’s latest rating changes from various analysts - knoxdaily.com
Tharimmune Inc (THAR) Stock: Uncovering 52-Week Market Trends - investchronicle.com
These Numbers Show Just How Powerful Tharimmune Inc (NASDAQ: THAR) Stock Is - Stocksregister
Tharimmune expands board, appoints new directors By Investing.com - Investing.com Nigeria
Tharimmune expands board, appoints new directors - Investing.com
FDA Nods to Tharimmune’s Countermeasure for Opioid Threats By Investing.com - Investing.com South Africa
FDA Nods to Tharimmune’s Countermeasure for Opioid Threats - Investing.com Australia
Now Is The Time To Build A Position In Tharimmune Inc (NASDAQ:THAR) - Marketing Sentinel
Observations on the Tharimmune Inc (NASDAQ:THAR) Growth Curve - uspostnews.com
Tharimmune (THAR) Advances TH104 with FDA Feedback on New Drug A - GuruFocus
Tharimmune (THAR) Advances TH104 with FDA Feedback on New Drug Application | THAR Stock News - GuruFocus
Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback - The Joplin Globe
FDA Clears Path for Tharimmune's Military-Grade Fentanyl Defense Drug: No New Trials Needed - Stock Titan
Tharimmune Inc Azioni (THAR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tharimmune Inc Azioni (THAR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Parikh Sanam | Director |
Jun 20 '25 |
Buy |
1.45 |
1,000 |
1,450 |
1,770 |
| Appajosyula Sireesh | Chief Executive Officer |
Jun 20 '25 |
Buy |
1.48 |
61,496 |
90,973 |
64,868 |
| Parikh Sanam | Director |
May 15 '25 |
Buy |
1.30 |
770 |
1,001 |
770 |
| MILBY RANDY | CEO |
Dec 19 '24 |
Buy |
2.12 |
4,600 |
9,752 |
17,534 |
| Appajosyula Sireesh | Chief Operating Officer |
Nov 13 '24 |
Buy |
2.02 |
5,000 |
10,096 |
10,758 |
| MILBY RANDY | CEO |
Oct 08 '24 |
Buy |
2.09 |
2,500 |
5,221 |
12,934 |
| Appajosyula Sireesh | Chief Operating Officer |
Oct 08 '24 |
Buy |
1.93 |
5,000 |
9,650 |
16,364 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):